Curated News
By: NewsRamp Editorial Staff
August 03, 2026

LataMed AI Partners with Droguerias Lala to Develop AI Tools for Pharma Labs

Discuss on LinkedIn Discuss on X, formerly Twitter Discuss on Substack Discuss on Telegram participate in discussion on bluesky Participate in discussion on Mastodon View History of this news story on GitHub
Original Source

TLDR

  • LataMed AI's new agreement with Droguerias Lala positions it to capture the pharmaceutical AI market in Latin America, offering a competitive edge.
  • The collaboration will design, develop, and test AI tools for pharmaceutical workflows, focusing on automation, quality control, and data analysis.
  • This AI aims to improve pharmaceutical safety and efficiency in Latin America, supporting professionals without replacing their judgment.
  • LataMed AI and Droguerias Lala will develop AI for labs, potentially expanding to other organizations in the region.

Impact - Why it Matters

This collaboration is significant because it applies AI to the pharmaceutical and laboratory sector, which could enhance efficiency and accuracy in drug development and quality control. For the healthcare industry, it represents a step toward integrating AI in critical workflows, potentially leading to faster research and safer products. For investors, it signals LataMed's expansion beyond telemedicine, potentially opening new revenue streams. Ultimately, this could improve healthcare outcomes in Latin America by supporting professionals with advanced tools, while ensuring human oversight remains paramount.

Summary

LataMed AI Corp. (OTC: LMED), a healthcare technology company focused on digital health and AI solutions for Latin America, has announced a new collaboration with DROGUERIAS LALA C.A., a Venezuelan pharmaceutical distributor. The agreement, signed through LataMed's Venezuelan subsidiary LATAMEDAI VE, aims to develop AI-supported and automated software tools for pharmaceutical and laboratory operations. These tools are intended to streamline workflows in pharmaceutical research, laboratory testing, quality control, documentation, and data analysis, potentially including features like workflow automation, testing coordination, document management, and predictive analytics to help identify inconsistencies early.

The partnership will start by identifying specific workflows and defining technical requirements, with a phased development and testing process. Importantly, the technology is designed as a decision-support tool, not to replace professional judgment; all pharmaceutical, scientific, and regulatory decisions remain with qualified professionals. Dr. Kevin Rodan Levy, CEO of LataMed AI, emphasized the goal of applying AI responsibly while preserving oversight. This initiative aligns with LataMed's broader strategy to expand its technology beyond telemedicine into enterprise pharmaceutical and laboratory applications, potentially adaptable for other organizations in Latin America.

The agreement sets a framework for collaboration but does not guarantee a specific timeline, commercial deployment, or revenue. LataMed AI will provide updates as development progresses. The company also highlighted its ongoing AI platforms, CardioAI, PulmoAI, and NeuroAI, which are in development. This collaboration marks a significant step for LataMed in diversifying its AI applications in healthcare. For more details, visit https://latamed.ai or review SEC filings at www.sec.gov. The original release can be found on www.newmediawire.com.

Source Statement

This curated news summary relied on content disributed by NewMediaWire. Read the original source here, LataMed AI Partners with Droguerias Lala to Develop AI Tools for Pharma Labs

blockchain registration record for this content.